Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/autre/the-21st-century-handbook-of-clinical-ovarian-cancer/tewari/descriptif_3269807
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=3269807

The 21st Century Handbook of Clinical Ovarian Cancer, 2015

Langue : Anglais

Auteurs :

Couverture de l’ouvrage The 21st Century Handbook of Clinical Ovarian Cancer
A thorough review on ovarian cancer, treatment guidelines and emerging therapies available for the disease. The book was originally commissioned due to recent developments in therapies for ovarian cancer. This concise pocket book will review ovarian cancer?s epidemiology, clinical features, diagnosis and medical management. Busy healthcare professionals will benefit from this text, which will not only cover the foundation of ovarian cancer management, but discuss up-to-date national and international treatment guidelines and upcoming therapies.
Treatment Guidelines.- Emerging Therapies.- Epidemiology.- Clinical Features.- Diagnosis.- Medical management.

Krishnansu S Tewari, MD, is a Professor and Director of Research in the Division of gynecologic oncology at the University of California (UC) Irvine. He received his bachelor’s degree in molecular biology at UC Berkeley, and went to medical school, completed his residency in obstetrics and gynecology, and fellowship in gynecologic oncology at the UC Irvine. He serves as the Principal Investigator of the National Cancer Institute’s NRGOncology Cooperative Group and Gynecologic Oncology Group Partners at UC Irvine. At UC Irvine, Dr Tewari is the Chairman of the Clinical Trials Protocol Review and Monitoring Committee and the Director of the Women's Disease Oriented Team for the Chao Family National Cancer Institute Designated Comprehensive Cancer Center. He is also the Director of the Gynecologic Oncology Program at St Joseph’s Center for Cancer Prevention and Treatment. Dr Tewari is a voting member of the NRG’s Cervix Committee,

Publications Committee, and Committee on Experimental Medicine, and Chairs the Society of Gynecologic Oncology’s Publications Committee. Dr Tewari has published over 100 peer-reviewed articles and written numerous book chapters. His research interests include novel targeted therapeutics in ovarian cancer and cervical cancer. Dr Tewari is funded by the National Institutes of Health to study surrogate markers of angiogenesis in cervical cancer and is the Study Chair/Principal Investigator for Gynecologic Oncology Group protocol 240, the practice-changing phase III randomized clinical trial, which demonstrated that compared with chemotherapy alone, the addition of the anti-angiogenesis drug, bevacizumab, significantly improved overall survival, progression-free survival, and response rate without a significant deterioration in health-related quality of life (Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370:734‑743). This pivotal trial led to US

A comprehensive guide on major national and international diagnosing, staging and treatment guidelines for ovarian cancer

Easily accessible text, figures and illustrations offer practical approaches for managing and understanding ovarian cancer

A thorough and concise book for healthcare professionals to better understand the background and development of ovarian cancer

Includes supplementary material: sn.pub/extras

Date de parution :

Ouvrage de 200 p.

12.7x20.1 cm

Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).

52,74 €

Ajouter au panier

Thème de The 21st Century Handbook of Clinical Ovarian Cancer :